Studies related to Cognitive Decline and Curcumin

Six-month Randomized, Placebo-controlled, Double-blind, Pilot Clinical Trial Of Curcumin In Patients With Alzheimer Disease

Effect Decrease
Trial Design Double blind
Trial Length 1-6 months
Number of Subjects 27
Sex Both Genders
Age Range 45-64, 65+
Notes for this study:
In a double-blind 6 month controlled trial conducted in 50+ year olds with memory decline, investigating 1 or 4g curcumin daily (against placebo).

Serum amyloid-beta pigmentation and isoprostanes did not differ between groups, although a non-significant trend was shown for serum levels of AB to rise.

As measured by the MMSE, a rising of the rating scale in placebo by 1.3 points (indicating a decline of cognitive capacity) seems to have been mitigated in experimental groups, although not reversed.